Warfarin - How Good Are we at Maintaining Target Range ?

This study is ongoing, but not recruiting participants.
NHS Tayside
Information provided by:
University of Dundee
ClinicalTrials.gov Identifier:
First received: March 4, 2010
Last updated: June 24, 2010
Last verified: March 2010
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.

Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Retrospective
Official Title: Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.

Resource links provided by NLM:

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Bleeding Complication [ Time Frame: 10 years ]
    Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.

  • Cardiovascular outcome [ Time Frame: 10 years ]
    Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event

Estimated Enrollment: 5000
Study Start Date: March 2010
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Patients receiving Warfarin


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients receiving Warfarin for lone atrial fibrillation

Inclusion Criteria:

  • Prescription for Warfarin
  • Atrial Fibrillation

Exclusion Criteria:

  • Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
  • Conditions with increased risk of bleeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01081327

United Kingdom
Centre for Cardiovascular and Lung Biology, Univeristy of Dundee
Dundee, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
NHS Tayside
  More Information

Responsible Party: Dr. Douglas Elder, University of Dundee
ClinicalTrials.gov Identifier: NCT01081327     History of Changes
Other Study ID Numbers: ELD007 
Study First Received: March 4, 2010
Last Updated: June 24, 2010

Keywords provided by University of Dundee:
Atrial Fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on January 19, 2017